Litcius/Paper detail

Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study

Diane Goèré, Olivier Gléhen, François Quénet, Jean‐Marc Guilloit, Jean-Marc Béréder, G. Lorimier, Emilie Thibaudeau, Laurent Ghouti, Amandine Pinto, Jean‐Jacques Tuech, Réza Kianmanesh, Michel Carretier, Frédéric Marchal, C. Arvieux, Cécile Brigand, Pierre Méeus, Patrick Rat, Sylvaine Durand‐Fontanier, Pascale Mariani, Zaher Lakkis, Valeria Loi, N. Pirró, Charles Sabbagh, Matthieu Texier, Dominique Élias, Michel Ducreux, David Malka, Valérie Boige, E Benhamou

2020The Lancet Oncology230 citationsDOIOpen Access PDF

Topics & Concepts

MedicineHyperthermic intraperitoneal chemotherapyOxaliplatinColorectal cancerSurgeryIrinotecanInternal medicineOvarian cancerCancerCytoreductive surgeryIntraperitoneal and Appendiceal MalignanciesNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study | Litcius